Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.

M A Faulkner, E C Wadibia, B D Lucas, D E Hilleman

Journal: Pharmacotherapy 2000;20(4):410-6

PMID: 10772372

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

This randomized, controlled trial evaluated the impact of personalized follow-up on compliance rates in high-risk patients receiving combination lipid-lowering therapy over 2 years. A random sample of 30 patients 7-30 days after cardiac surgery had baseline fasting low-density lipoprotein levels higher than 130 mg/dl. All patients received lovastatin 20 mg/day and colestipol 5 g twice/day. Weekly telephone contact was made with each patient for 12 weeks. Short- and long-term compliance was assessed by pill and packet counts and refill records. Compliance and lipid profile results were significantly better in the intervention group (p<0.05) up to 2 years after the start of therapy than in the control group for all parameters except high-density lipoprotein. However, this effect was not apparent during the first 12 weeks of therapy. Short-term telephone follow-up favorably affected compliance and lipid profile results up to 2 years after start of therapy.

Address: Department of Pharmacy Practice, Creighton University School of Pharmacy and Allied Health Professions, Omaha, Nebraska 68178, USA.

DOI: 10.1592/phco.20.5.410.35048

Link outs

Free resources

Medical:

https://medlineplus.gov/cholesterolmedicines.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Aged, Cholesterol, Colestipol, Coronary Disease, Counseling, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypolipidemic Agents, Lipoproteins, HDL, Lipoproteins, LDL, Lovastatin, Male, Middle Aged, Myocardial Revascularization, Patient Compliance, Pharmacists, Time Factors, Treatment Outcome, Triglycerides